


# Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience

Corrado Girmenia, Anna Maria Frustaci, Giuseppe Gentile, Clara Minotti, Claudio Cartoni, Saveria Capria, Silvia Maria Trisolini, Angela Maturro, Giuseppina Loglisci, Roberto Latagliata, Massimo Breccia, Giovanna Meloni, Giuliana Alimena, Robin Foà, and Alessandra Micozzi

Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa, Azienda Policlinico Umberto I, "Sapienza" University of Rome, Italy

Citation: Girmenia C, Frustaci AM, Gentile G, Minotti C, Cartoni C, Capria S, Trisolini SM, Maturro A, Loglisci G, Latagliata R, Breccia M, Meloni G, Alimena G, Foà R, and Micozzi A. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. *Haematologica* 2012;97(4):560-567. doi:10.3324/haematol.2011.053058



Online Supplementary Figure S1. Flow charts of chemotherapy cycles, prophylaxis treatments and proven/probable invasive fungal diseases (PP-IFD) documented during the front-line chemotherapy of patients with AML in the control group (A) and in the posaconazole group (B). PAP = primary antifungal prophylaxis; SAP = secondary antifungal prophylaxis